CTKB Cytek Corp Expected net earnings per share growth this year

The annual change in EPS reflects the profit dynamics of Cytek Biosciences, Inc. (CTKB), where the current value is 44.60. Growth in these metrics is driven by the sale of advanced cytometers to medical centers and pharmaceutical companies. Business development relies on a staff of high-caliber bioinformaticians and engineers. Meanwhile, Cytek Biosciences, Inc. (CTKB) maintains its position in cell analysis through unique patents, resisting pricing pressure from large medical conglomerates.

Cytek Biosciences, Inc. (CTKB): Net earnings per share growth this year from 07/04/2022 to 11/11/2026

Financial and market metric breakdowns for Cytek Biosciences, Inc. (CTKB)

- current quotes and average value forecast:

Market Chart Cytek Biosciences Inc|CTKB - Price Target Chart

- market capitalization data:

Market Capitalization Cytek Corp|CTKB - Enterprise Value

- shareholders' equity book value data:

Accounting Value per Share Cytek Biosciences|CTKB - Company Net Assets|Market-to-Book Ratio cytekbio.com|CTKB - Cumulative Company Assets

- debt burden and liquidity indicators:

- net income and valuation ratios data:

CTKB - Net Profit|Company Profit Forecast Cytek Biosciences, Inc.|CTKB - Price to Earnings Ratio|Projected Price to Earnings Ratio Cytek Corp|CTKB - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Cytek Corp|CTKB - Operating profit EBITDA|Net earnings per share for the last 12 months Cytek Biosciences|CTKB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months cytekbio.com|CTKB - Earnings growth in current year|Expected net earnings per share growth next year Cytek Biosciences, Inc.

Basic company analysis:Cytek Biosciences, Inc.

To distinguish fundamentally resilient assets from speculative ones, the year-over-year growth rate of earnings per share is calculated, which measures the actual efficiency of capitalization. By analyzing the annual earnings per share dynamics, an investor can see the smoothed growth trajectory of Cytek Biosciences (CTKB), whose biomedical innovations are shielded from geopolitical sanctions, confirming the high investment resilience of the business.

Key competitors